The prevention and treatment of delirium in elderly patients following hip fracture surgery

Recent Patents on CNS Drug Discovery

Volumn 10, Issue 1, 2015, Pages 55-64

  Martocchia, Antonio ^a   Curto, Martina ^a   Comite, Fabrizia ^a   Scaccianoce, Sergio ^a   Girardi, Paolo ^a   Ferracuti, Stefano ^a   Nicoletti, Ferdinando ^a   Falaschi, Paolo ^a   De Marinis, Elisabetta ^b   Stefanelli, Manuela ^b   Toussan, Lavinia ^b   Devito, Antonio ^b   Giordano, Stefania ^b   Pastore, Francesca ^b   Indiano, Ilaria ^b   Eleuteri, Stefano ^b   Maccari, Lisa ^b   Falaschi, Giulia Maria ^b   De Luca, Assunta ^b   Galletta, Matteo ^b   Turci, Carlo ^b   Ladaga, Paola ^b   Luciani, Cristiana ^b   Ientile, Antonio ^b   Vaglio, Stefania ^b   Catanese, Maria ^b   Vulpiani, Maria Chiara ^b   Fiorani, Laura ^b   Galassi, Andrea ^b   Simeoni, Letizia ^b   Ferri, Enrico ^b   Tafaro, Laura ^b   March, Massimiliano Rocchietti ^b   Benvenuto, Rosalba ^b   D’Arrigo, Carmelo ^b   Di Somma, Salvatore ^b   Volpe, Massimo ^b   Pinto, Giovanni ^b   Ferretti, Andrea ^b   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer s disease; BDNF; Cortisol; Hip fracture; Metabolism; Neurotransmission

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; DELIRIUM; GABAERGIC TRANSMISSION; HIP FRACTURE; HUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; ADVERSE EFFECTS; GERIATRIC ASSESSMENT; HIP FRACTURES; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATIONS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DELIRIUM; GERIATRIC ASSESSMENT; HIP FRACTURES; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS;

EID: 84938697271     PISSN: 15748898     EISSN: 22123954     Source Type: Journal    
DOI: 10.2174/1574889810666150216152624     Document Type: Article

References (149)

1. Chesser TJS, Handley R, Swift C. New NICE guideline to improve outcomes for hip fracture patients. Injury Int J Care Injured 2001; 42: 727-29.
2. Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006; 203: 865-77.
3. Inouye SK. Delirium after hip fracture: To be or not to be? J Am Geriatr Soc 2001; 49: 678-9.
4. National Institute for Health and Clinical Excellence Delirium Draft Guideline Consultation. Delirium: Diagnosis, prevention and management. 2010. http://www.nice.org.uk/guidance/CG103.
5. Bruce AJ, Ritchie CW, Blizard R, Lai R, Raven P. The incidence of delirium associated with orthopedic surgery: A meta-analytic review. Int Psychogeriatr 2007; 19: 197-214.
6. de Castro SM, Unlu C, Tuynman JB, Honig A, van Wagensveld BA, Steller EP, et al. Incidence and risk factors of delirium in the elderly general surgical patient. Am J Surg 2014; 208: 26-32.
7. Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. Arch Intern Med 2008; 168: 27-32.
8. Dasgupta M, Dumbrell AC. Preoperative risk assessment for delirium after noncardiac surgery: A systematic review. J Am Geriatr Soc 2006; 54: 1578-89.
9. Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, Haslauer CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. JAMA 1994; 271: 134-9.
10. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA 1996; 275: 852-7.
11. van Munster BC, Korse CM, de Rooij SE, Bonfrer JM, Zwinderman AH, Korevaar JC. Markers of cerebral damage during delirium in elderly patients with hip fracture. BMC Neurol 2009; 9: 21.
12. Handoll HH, Queally JM, Parker MJ. Pre-operative traction for hip fractures in adults. Cochrane Database Syst Rev 2011; 7: CD000168.
13. Takayama H, Mizukawa K, Ota Z, Ogawa N. Regional responses of rat brain muscarinic cholinergic receptors to immobilization stress. Brain Res 1987; 436: 291-5.
14. Olofsson K, Alling C, Lundberg D, Malmros C. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand 2004; 48: 679-84.
15. Cornelius C, Koverech G, Crupi R, Di Paola R, Koverech A, Lodato F, et al. Osteoporosis and Alzheimer pathology: Role of cellular stress response and hormetic redox signaling in aging and bone remodeling. Front Pharmacol 2014; 5: 120.
16. Alagiakrishnan K, Wiens CA. An approach to drug induced delirium in the elderly. Postgrad Med J 2004; 80: 388-93.
17. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: A systematic review. Age Ageing 2011; 40: 23-9.
18. Flacker JM, Lipsitz LA. Neural mechanisms of delirium: Current hypotheses and evolving concepts. J Gerontol A Biol Sci Med Sci 1999; 54: B239-46.
19. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): Consensus validation. Int J Clin Pharmacol Ther 2008; 46: 72-83.
20. NHS Cumbria Medicines Management Information available from: www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Ho me.aspx 2011.
21. Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987; 8: 521-45.
22. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med 2009; 122: 605-13.
23. Wacker P, Nunes PV, Cabrita H, Forlenza OV. Post-operative delirium is associated with poor cognitive outcome and dementia. Dement Geriatr Cogn Disord 2006; 21: 221-7.
24. Rösler A, von Renteln-Kruse W, Mühlhan C, Frilling B. Treatment of dementia patients with fracture of the proximal femur in a specialized geriatric care unit compared to conventional geriatric care. Z Gerontol Geriat 2012; 45: 400-3.
25. McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: Occurrence and clinical course in older patients. J Am Geriatr Soc 2003; 51: 591-8.
26. Lowery DP, Wesnes K, Ballard CG. Subtle attentional deficits in the absence of dementia are associated with an increased risk of post-operative delirium. Dement Geriatr Cogn Disord 2007; 23: 390-4.
27. Patorno E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT. Comparative safety of anesthetic type for hip fracture surgery in adults: Retrospective cohort study. BMJ 2014 27; 348: g4022.
28. Gupta N. Delirium: Another factor when considering type of anesthetic for hip fracture surgery in adults. BMJ 2014; 349: g4871.
29. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means of assessing risk of delirium. Am J Psychiatr 1992; 149: 1393-4.
30. Flacker JM, Lipsitz LA. Serum anticholinergic activity changes with acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci 1999; 54: M12-6.
31. van der Mast RC. Pathophysiology of delirium. J Geriatr Psychiatry Neurol 1998; 11: 138-45.
32. Trzepacz PT, Ho V, Mallavarapu H. Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's disease. Psychosomatics 1996; 37: 299-301.
33. Lim SA, Kang UJ, McGehee DS. Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci 2014; 6: 22.
34. Golden RN, James SP, Sherer MA, Rudorfer MV, Sack DA, Potter WZ. Psychoses associated with buproprion treatment. Am J Psychiatr 1985; 142: 1459-62.
35. Pycock CJ, Carter CJ, Kerwin RW. Effect of 6-hydroxy-dopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. J Neurochem 1980; 34: 91-9.
36. van Munster BC, Yazdanpanah M, Tanck MW, de Rooij SE, van de Giessen E, Sijbrands EJ, et al. Genetic polymorphisms in the DRD2, DRD3, and SLC6A3 gene in elderly patients with delirium. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 38-45.
37. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
38. Perez SM, Lodge DJ. New approaches to the management of schizophrenia: Focus on aberrant hippocampal drive of dopamine pathways. Drug Des Devel Ther 2014; 8: 887-96.
39. Adams W, Morandi A, Girard TD, Thompson JL, Boomershine CS, Shintani AK, et al. The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness. Crit Care Med 2012; 40: 835-41.
40. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355-66.
41. O'Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 2015; 277: 32-48.
42. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-77.
43. de Jonghe A, van Munster BC, Fekkes D, van Oosten HE, de Rooij SE. The tryptophan depletion theory in delirium: Not confirmed in elderly hip fracture patients. Psychosomatics 2012; 53: 236-43.
44. Robinson TN, Raeburn CD, Angles EM, Moss M. Low tryptophan levels are associated with postoperative delirium in the elderly. Am J Surg 2008; 195: 670-4.
45. Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R. Pharmacology of hallucinations: Several mechanisms for one single symptom? Biomed Res Int 2014; 2014: 307106.
46. Saudou F, Hen R. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem Int 1994; 25: 503-32.
47. van der Mast RC, Fekkes D, Moleman P, Pepplinkhuizen L. Is postoperative delirium related to reduced plasma tryptophan? Lancet 1991; 338: 851-2.
48. Maldonado JR. Neuropathogenesis of delirium: Review of current etiologic theories and common pathways. Am J Geriatr Psychiatry 2013; 21: 1190-222.
49. Maldonado JR. Pathoetiological model of delirium: A comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment. Crit Care Clin 2008; 24: 789-856.
50. Unseld E, Ziegler G, Gemeinhar A, Janssen V, Klotz U. Possible interaction of fluroquinilones wih the benzodiazepine-GABAAreceptor complex. Br Clin Pharmacol 1990; 30: 63-70.
51. Farrington J, Stoudmire A, Tierney J. The role of ciprofloxacin in a patient with delirium due to multiple etiologies. Gen Hosp Psychiatry 1995; 17: 47-53.
52. Adams JM, Thomas P, Smart TG. Modulation of neurosteroid potentiation by protein kinases at synaptic- and extrasynaptic-type GABAA receptors. Neuropharmacology 2015; 88: 63-73.
53. Guo D, Hu J. Spinal presynaptic inhibition in pain control. Neuroscience 2014; 283C: 95-106.
54. Graham DG. Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 1984; 5: 83-95.
55. Lei S. Cross interaction of dopaminergic and adrenergic systems in neural modulation. Int J Physiol Pathophysiol Pharmacol 2014; 6: 137-42.
56. McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin JC, Sing HC, et al. Sleep deprivation and impaired cognition: Possible role of brain catecholamines. Biol Psychiatr 1992; 31: 1082-97.
57. Siejsjo B. Brain energy metabolism and catecholaminergic activity in hypoxia, hypercapnia, and ischemia. J Neural Transm 1978; 14(Supp): 17-22.
58. Girard TD. Brain dysfunction in patients with chronic critical illness. Respir Care 2012; 57: 947-55; discussion 955-7.
59. Ross CA. CNS arousal systems: Possible role in delirium. Int Psychogeriatr 1991; 3: 353-71.
60. Tsai G, Coyle IT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Ann Rev Med 1998; 49: 173- 84.
61. Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R. Pharmacology of hallucinations: Several mechanisms for one single symptom? BioMed Research International 2014; article ID 307106, 9 pages.
62. Fell MJ, McKinzie DL, Monn JA, Svensson KA. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012; 62: 1473-83.
63. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-77.
64. van Munster BC, Bisschop PH, Zwinderman AH, Korevaar JC, Endert E, Wiersinga WJ, et al. Cortisol, interleukins and S100B in delirium in the elderly. Brain Cogn 2010; 74: 18-23.
65. Rosenberg S, Loetz M, Yang J. Experience with the use of highdose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-84.
66. Team A, Matsumura H, Saito M. Interleukin-l induces slow-wave sleep at the prostaglandin D2-sensitive sleep-promoting zone in the rat brain. J Neurosci 1998; 18: 6599-607.
67. Westhoff D, Witlox J, Koenderman L, Kalisvaart KJ, de Jonghe JF, van Stijn MF, et al. Preoperative cerebrospinal fluid cytokine levels and the risk of postoperative delirium in elderly hip fracture patients. J Neuroinflamm 2013; 10: 122.
68. de Rooij SE, Zeerleder S, Burtman D, van Munster BC. Nucleosomes in individuals with hip fracture with and without delirium. J Am Geriatr Soc 2014; 62: 395-6.
69. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-28.
70. Sun T, Wang X, Liu Z, Chen X, Zhang J. Plasma concentrations of pro- and anti-inflammatory cytokines and outcome prediction in elderly hip fracture patients. Injury, Int J Care Injured 2011; 42: 707-13.
71. van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE. Time course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc 2008; 56: 1704-9.
72. McIntosh TK, Bush HL, Yetson NS, Grasberger R, Palter M, Aun F, et al. Beta-endorphin, cortisol, and postoperative delirium: A preliminary report. Psychoneuroendocrinology 1985; 10: 303-13.
73. Uno H, Eisele S, Sakai A, Shelton S, Baker E, DeJesus O, et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994; 28: 336-48.
74. McKieth IG. Clinical use of the DST in a psychogeriatric population. Br J Psychiatr 1984; 145: 389-93.
75. Maldonado J. An approach to the patient with substance use and abuse. Med Clin North Am 2010; 94: 1169-205.
76. Falaschi P, Martocchia A, Proietti A, Pastore R, D'Urso R. Immune system and the hypothalamus-pituitary-adrenal axis. Common words for a single language. Ann NY Acad Sci 1994; 741: 223-33.
77. Kudoh A, Ishihara H, Matsuki A. Response to surgical stress in elderly patients and Alzheimer's disease. Can J Anesth 1999; 46: 247-52.
78. Landfield PW, Blalock EM, Chen KC, Porter NM. A new glucocorticoid hypothesis of brain aging: Implications for Alzheimer's Disease. Curr Alzh Res 2007; 4: 205-12.
79. Martocchia A, Curto M, Toussan L, Stefanelli M, Falaschi P. Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Rec Pat CNS Drug Discov 2011; 6: 196-204.
80. Stefanelli M, Martocchia A, De Marinis A, Falaschi P. Prevalence of metabolic syndrome in cognitive impairment: The possible role of malnutrition. Aging Clin Exp Res 2013; 25: 351-2.
81. Martocchia A, Stefanelli M, Falaschi GM, Toussan L, Rocchietti MM, et al. Targets of anti-glucocorticoid therapy for stress-related diseases. Rec Pat CNS Drug Discov 2013; 8: 79-87.
82. Ahboucha S, Butterworth RF. The neurosteroid system: Implication in the pathophysiology of hepatic encephalopathy. Neurochem Int 2008; 52: 575-87.
83. Martocchia A, Curto M, Comite F, Scaccianoce S, Xenos D, Nasca C, et al. NeuroEndocrine-Immunology in orthogeriatric patients: Preliminary report on the acute modification of urinary cortisol and serum BDNF levels in Alzheimer's disease after osteoporotic hip fracture. 5° Congr NEIRD, Santa Margherita Ligure, Italy. Clin Exp Rheumatol 2013; 31: 835.
84. Erickson KI, Prakash RS, Voss MW, Chaddock L, Heo S, McLaren M, et al. Brain-derived neurotrophic factor is associated with agerelated decline in hippocampal volume. J Neurosci 2010; 30: 5368- 75.
85. Curto M, Martocchia A, Comite F, Scaccianoce S, Xenos D, Nasca C, et al. The presence of depressive symptoms in comorbidity with Alzheimer Disease does not influence changes in serum brainderived neurotrophic factor levels in older patients. Int J Geriatr Psych 2014; 29: 439-40.
86. Martocchia A, Curto M, Scaccianoce S, Comite F, Xenos D, Nasca C, et al. Effects of escitalopram on serum BDNF levels in elderly patients with depression: A preliminary report. Aging Clin Exp Res 2014; 26: 461-4.
87. Evans P. Free radicals in brain metabolism and pathology. Br Med Bull 1993; 49: 577-87.
88. Kaufman S. An evaluation of the possible neurotoxicity of metabolites of phenylalanine. J Ped 1989; 114: 895-900.
89. Jeppson B, Freund H, Gimmon Z, James J, von Mayenfeldt M, Fischer J. Blood-brain barrier derangement in sepsis: Cause of septic encephalopathy? Am J Surg 1981; 141: 136-42.
90. Ng T, Graham DI, Adams JH, Ford I. Changes in the hippocampus and the cerebellum resulting from hypoxic insults: Frequency and distribution. Acta Neuropathol 1989; 78: 438-43.
91. Mézière A, Paillaud E, Belmin J, Pariel S, Herbaud S, Canouï- Poitrine F, et al. Delirium in older people after proximal femoral fracture repair: Role of a preoperative screening cognitive test. Ann Fr Anesth Reanim 2013; 32: e91-6.
92. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
93. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 1989; 37: 725-9.
94. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The minicog: A cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatr 2000; 15: 1021-7.
95. Belmin J, Pariel-Madjlessi S, Surun P, Bentot C, Feteanu D, Lefebvre des Noettes V, et al. The cognitive disorders examination (Codex) is a reliable 3-minute test for detection of dementia in the elderly (validation study on 323 subjects). Press Med 2007; 36: 1183-90.
96. Robinson TN, Wu DS, Pointer LF, Dunn CL, Moss M. Preoperative cognitive dysfunction is related to adverse postoperative outcomes in the elderly. J Am Coll Surg 2012; 215: 12-7.
97. Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Development and cross-validation. Psychol Med 1994; 24: 145-53.
98. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989; 19: 1015- 22.
99. Anita S, Lars S, Sari P, Jan T. Documenting the cognitive status of hip fracture patients using the Short Portable Mental Status Questionnaire. Scand J Caring Sci 2006; 15: 308-13.
100. Fillenbaum GG. Comparison of two brief tests of organic brain impairment, the MSQ and the short portable MSQ. J Am Geriatr Soc 1980; 28: 381-4.
101. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder: DSM-5. Arlington, VA: American Psychiatric Publishing, 2013.
102. van Munster BC, de Rooij SE. Delirium: A synthesis of current knowledge. Clin Med 2014; 14: 192-5.
103. Grover S, Kate N. Assessment scales for delirium: A review. World J Psychiatr 2012; 2: 58-70.
104. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. Classifying neurocognitive disorders: The DSM-5 approach. Nat Rev Neurol 2014; 10: 634-42.
105. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990; 113: 941-8.
106. Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The Delirium Observation Screening Scale: A screening instrument for delirium. Res Theory Nurs Pract 2003; 17: 31-50.
107. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 1988; 23: 89-97.
108. de Rooij SE, van Munster BC, Korevaar JC, Casteelen G, Schuurmans MJ, Mast RC van der, et al. Delirium subtype identification and the validation of the Delirium Rating Scale- Revised-98 (Dutch version) in hospitalized elderly patients. Int J Geriatr Psychiatry 2006; 21: 876-82.
109. Hakim SM, Othman AI, Naoum DO. Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: A randomized trial. Anesthesiology 2012; 116: 987-97.
110. Liptzin B, Levkoff SE. An empirical study of delirium subtypes. Br J Psychiatry 1992; 161: 843-45.
111. Leentjens AF, Molag ML, Van Munster BC, De Rooij SE, Luijendijk HJ, Vochteloo AJ, et al. Changing perspectives on delirium care: The new Dutch guideline on delirium. J Psychosom Res 2014; 77: 240-1.
112. Neelon VJ, Champagne MT, Carlson JR, Funk SG. The NEECHAM Confusion Scale: Construction, validation, and clinical testing. Nurs Res 1996; 45: 324-30.
113. Hargreaves, T., MacLullich, E.A., Brown, L., Adler, J. Apparatus and method for testing sustained attention and delirium. WO2011042703 (2011).
114. Grant PM, Ryan CG, Tigbe WW, Granat MH. The validation of a novel activity monitor in the measurement of posture and motion during everyday activities. Br J Sports Med 2006; 40: 992-7.
115. Van Der Heide, E.M., Heinrich, A., Falck, T. Monitoring system for monitoring a patient and detecting delirium of the patient. EP2747647 (2014).
116. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-13.
117. Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry 2013; 21: 785- 93.
118. Watne LO, Hall RJ, Molden E, Raeder J, Frihagen F, MacLullich AM, et al. Anticholinergic activity in cerebrospinal fluid and serum in individuals with hip fracture with and without delirium. J Am Geriatr Soc 2014; 62: 94-102.
119. Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology; 75: 152-9.
120. Kidd AC, Musonda P, Soiza RL, Butchart C, Lunt CJ, Pai Y, et al. The relationship between total anticholinergic burden (ACB) and early in-patient hospital mortality and length of stay in the oldest old aged 90 years and over admitted with an acute illness. Arch Gerontol Geriatr 2014; 59: 155-61.
121. Tune L, Coyle IT. Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics. Psychopharmachology 1981; 75: 9-15.
122. Mangoni AA, van Munster BC, Woodman RJ, de Rooij SE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause post discharge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiat 2013; 21: 785-93.
123. Barroso, A.M., Falck, T. Lighting system, particularly for delirium reduction in intensive care units. WO2013175348 (2013).
124. Campbell N, Boustani MA, Ayub A, Fox GC, Munger SL, Ott C, et al. Pharmacological management of delirium in hospitalized adults - A systematic evidence review. J Gen Intern Med 2009; 24: 848-53.
125. Kalisvaart KJ, de Jonghe JF, Bogaards MJ, Vreeswijk R, Egberts TC, Burger BJ, et al. Haloperidol prophylaxis for elderly hip surgery patients at risk for delirium: A randomized placebocontrolled study. J Am Ger Soc 2005; 53: 1658-66.
126. Han C-S, Kim Y-K. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004; 45: 297-301.
127. Lee KU, Won WY, Lee HK, Kweon YS, Lee CT, Pae CU, et al. Amisulpride versus quetiapine for the treatment of delirium: A randomized, open prospective study. Int Clin Psychopharmacol 2005; 20: 311-4.
128. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs Haloperidol: Treating delirium in a critical care setting. Intensive Care Med 2004; 30: 444-9.
129. Meltzer HY. Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proc Natl Acad Sci USA 2007; 104: 3019-20.
130. Diaz V, Rodriguez J, Barrientos P, Serra M, Salina H, Toledo C, et al. Use of citicoline in the prevention of delirium in hip fracture surgery in elderly. A randomized controlled trial. Rev Neurol 2001; 33: 716-9.
131. Sampson EL, Raven PR, Ndhlovu PN, Vallance A, Garlick N, Watts J, et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry 2007; 22: 343-9.
132. Granacher R, Baldessarini R, Messner E. Physostigmine treatment of delirium induced by anticholinergics. Am Fam Physician 1976; 13: 99-103.
133. Beshore, D.C., Kuduk, S.D., DiPardo, R.M. Quinolinonepyrazolone M1 receptor positive allosteric modulators. US 20120196845 (2012).
134. Dinnell, K., Lightfoot, A.P., Marshall, H.R. Indole modulators of the alpha 7 nicotinic acetylcholine receptor. US20110034515 (2011).
135. Leung JM, Sands LP, Rico M, Petersen KL, Rowbotham MC, Dahl JB, et al. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology 2006; 67: 1251-3.
136. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABAB receptors. Physiol Rev 2004; 84: 835-67.
137. Kruszewski SP, Paczynski RP, Kahn DA. Gabapentin-induced delirium and dependence. J Psychiatr Pract 2009; 15: 314-9.
138. Ely, E.W., Girard, T.D. The Modifying the Impact of ICUAssociated Neurological Dysfunction-USA (MIND-USA) study. NCT01211522 (2014).
139. Riguet, E., Campo, B., Gibelin, A., Mhalla, K. Triazinedione derivatives as GABA.sub.B receptor modulators. US 20130123262 (2013).
140. Gasser, R., Hernandez, M.C., Thomas, A. Use of selective GABA A. alpha.5 negative allosteric modulators for the treatment of central nervous system conditions. US20120115839 (2012).
141. de Jonghe A, van Munster BC, Goslings JC, Kloen P, van Rees C, Wolvius R, et al. Effect of melatonin on incidence of delirium among patients with hip fracture: A multicentre, double-blind randomized controlled trial. CMAJ 2014; 186: E547-56.
142. Hebenstreit GF, Fellerer GF, Twerdy B, Pfeiffer KP, Zadravec S, Ferdinand P. L-tryptophan bei pradeliranten und delianten zustandsbildem. Infusionstherapie 1989; 16: 92-96.
143. Mizok B. Branched-chain amino acids in sepsis and hepatic failure. Arch Intern Med 1985; 145: 1284-8.
144. Ivashtchenko, A.V., Ivashchenko, A.A., Savchuk, N.F. Substituted 2-amino-3-(sulfonyl)pyrazolo[1,5-a]pyrimidines - serotonin 5- HT.sub.6 receptor antagonists, method for use thereof. US20130079350 (2013).
145. Conn, P.J., Lindsley, C.W., Stauffer, S.R., Bartolome-Nebreda, J.M., Conde-Ceide, S., Macdonald, G.J., Tong, H.M., Pena-Pinon, M.A., Alcazar-Vaca, M.J., Andres-Gil, J.I. Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors. US20130345206 (2013).
146. Iqbal, K., Grundke-Iqbal, I. Neurotrophic peptides. US20130157946 (2013).
147. Jalleh R, Koh K, Choi B, Liu E, Maddison J, Hutchinson MR. Role of microglia and toll-like receptor 4 in the pathophysiology of delirium. Med Hypotheses 2012; 79: 735-9.
148. Grigoryan KV, Javedan H, Rudolph JL. Orthogeriatric care models and outcomes in hip fracture patients: A systematic review and meta-analysis. J Orthop Trauma 2014; 28: e49-55.
149. Watne LO, Torbergsen AC, Conroy S, Engedal K, Frihagen F, Hjorthaug GA, et al. The effect of a pre- and postoperative orthogeriatric service on cognitive function in patients with hip fracture: Randomized controlled trial (Oslo Orthogeriatric Trial). BMC Med 2014; 12: 63.